#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Urea cycle disorder Arterial disorder Hepatic angiosarcoma Orthostatic hypotension T-cell lymphoma Chronic lymphocytic leukaemia refractory Chronic graft versus host disease in skin Adenocarcinoma gastric Ovarian cancer stage IV Prolymphocytic leukaemia Haemophilia B with anti factor IX Erythema Cortical dysplasia Chronic granulomatous disease B-cell small lymphocytic lymphoma refractory More trials…

    Learn about Rare Diseases

    Hereditary ataxia – Treatment Usher’s syndrome – Life with Disease Leiomyosarcoma recurrent – Treatment Immunodeficiency congenital – Life with Disease Stevens-Johnson syndrome Methylmalonic acidaemia Wolfram syndrome Primary mediastinal large B-cell lymphoma – Treatment Mantle cell lymphoma stage II – Trials in Disease Medulloblastoma recurrent – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sodium Chloride Albiglutide ALPROSTADIL Ecoo2 Busulfan Cenobamate Zipalertinib Pirtobrutinib Emapalumab AZD0292 Cloxacillin Dexlansoprazole Ucp4 Ganciclovir Acenocoumarol IHMA-2121908-1 Glutenin JNJ-75276617 Daxdilimab Atidarsagene Autotemcel More therapies…

    Learn about Your Condition

    Neuropathic arthropathy Tricuspid valve disease Peritoneal cancer index Sickle cell anaemia Aneurysm ruptured Tumour thrombosis Raynaud's phenomenon Anal cancer metastatic Macular degeneration Anal cancer Open angle glaucoma Benign prostatic hyperplasia Anal cancer recurrent Synovial sarcoma recurrent Retinal neovascularisation More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. General University Hospital Of Larissa

General University Hospital Of Larissa

P. O. Box 1425, Larissa, 411 10, Greece

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effectiveness and Safety of Secukinumab for Adults with Moderate to Severe Rotator Cuff Tendinopathy

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Other Analgesics And Antipyretics
    • Secukinumab
    Denmark Greece Hungary Italy Poland Spain

  • Study on Zetomipzomib for Patients with Active Lupus Nephritis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Lupus nephritis
    Investigated Drugs:
    • Water For Injection
    • Zetomipzomib
    • Methylprednisolone Sodium Succinate
    Croatia France Germany Greece Italy Portugal +1

  • Study of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Adagrasib
    • Carboplatin
    • Cisplatin
    France Greece Hungary Italy Poland Spain

  • Study of LY3502970 for Adults with Obesity or Overweight and Type 2 Diabetes

    Not recruiting

    3 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    • Obesity
    • Overweight
    Czechia Germany Greece

  • Study on the Effects of MBS2320 for Patients with Idiopathic Pulmonary Fibrosis (IPF)

    Not recruiting

    2 1
    Investigated Diseases:
    • Idiopathic pulmonary fibrosis
    Investigated Drugs:
    • Mbs2320
    France Germany Greece Hungary Italy Spain

  • Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

    Not recruiting

    3 1
    Investigated Drugs:
    • Asundexian
    Austria Belgium Bulgaria Czechia Denmark Finland +14

  • Study on the Effectiveness of Weekly IcoSema (Insulin Icodec and Semaglutide) vs. Daily Insulin Glargine for Adults with Type 2 Diabetes Not Controlled by Oral Drugs

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Insulin Icodec
    • Insulin Glargine
    • Pioglitazone
    Greece Italy Poland

  • Study on the Effectiveness and Safety of BAY 3018250 and Low Molecular Weight Heparin for Patients with Proximal Deep Vein Thrombosis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Deep vein thrombosis
    • Thrombolysis
    Investigated Drugs:
    • Bay 3018250
    Belgium Bulgaria Czechia France Germany Greece +5

  • Study on the Effectiveness and Safety of Selinexor and Ruxolitinib for Patients with Myelofibrosis Who Have Not Received Prior Treatment

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Aprepitant
    • Ondansetron
    • Selinexor
    Belgium Bulgaria Czechia Denmark France Germany +7

  • Study of Zipalertinib with Chemotherapy vs. Chemotherapy Alone for Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Zipalertinib
    • Carboplatin
    • Cisplatin
    Belgium Bulgaria France Germany Greece Italy +4
Previous Page
1 … 16 17 18 19 20 21
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!